IDEAYA Biosciences, Inc.

As of October 3, 2025, IDEAYA Biosciences, Inc. shows a bullish trend supported by strong daily moving averages and weekly MACD, despite mixed signals from monthly indicators and underperformance compared to the S&P 500 over the past month and year.

As of October 3, 2025, IDEAYA Biosciences, Inc. shows a bullish technical trend with strong weekly indicators, outperforming the S&P 500 recently, although it lags behind in one-year returns.

As of October 3, 2025, IDEAYA Biosciences, Inc. shows a bullish trend with strong indicators, outperforming the S&P 500 in the short term but underperforming over the past year, while mixed signals persist in longer-term indicators.

As of September 8, 2025, IDEAYA Biosciences, Inc. has a mildly bullish trend, supported by strong short-term indicators despite mixed signals from longer time frames and a mildly bearish outlook from monthly Bollinger Bands.

As of November 12, 2020, IDEAYA Biosciences, Inc. is considered a risky investment due to its high valuation metrics and recent underperformance compared to peers and the S&P 500.

As of November 12, 2020, IDEAYA Biosciences, Inc. is considered overvalued and risky, with concerning financial ratios and a 1-year return of -42.09%, significantly underperforming the S&P 500's 10.26%.

As of June 17, 2025, IDEAYA Biosciences, Inc. shows a mildly bearish trend overall, with daily moving averages indicating bearishness, while weekly indicators present mixed signals of mild bullishness.

As of March 2022, the management team of IDEAYA Biosciences, Inc. includes Mr. Tim Shannon as Independent Chairman and Mr. Yujiro Hata as President and CEO, along with several independent directors on the Board.

IDEAYA Biosciences, Inc. is an oncology-focused precision medicine company that develops targeted therapeutics. As of March 2025, it has a market cap of approximately $1.92 billion and reported a net profit loss of $72 million.

As of Jun 18, IDEAYA Biosciences, Inc. has a market capitalization of 1,919.80 million, with net sales of 7.00 million and a net profit of -307.08 million over the latest four quarters. The company reported shareholder's funds of 1,059.15 million and total assets of 1,124.09 million as of Dec 24.